159 related articles for article (PubMed ID: 31158106)
1. Clinical implications of genetic aberrations in metastatic prostate cancer.
Reichert ZR; McKay RR
Curr Opin Urol; 2019 Jul; 29(4):319-325. PubMed ID: 31158106
[TBL] [Abstract][Full Text] [Related]
2. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in DNA Repair Pathway and Its Application in Personalized Care of Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Xu C; Mao S; Jiang H
Methods Mol Biol; 2020; 2204():75-89. PubMed ID: 32710316
[TBL] [Abstract][Full Text] [Related]
4. Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
Merseburger AS; Waldron N; Ribal MJ; Heidenreich A; Perner S; Fizazi K; Sternberg CN; Mateo J; Wirth MP; Castro E; Olmos D; Petrylak DP; Chowdhury S
Eur Urol; 2021 Apr; 79(4):519-529. PubMed ID: 33494937
[TBL] [Abstract][Full Text] [Related]
5. Real-world genetic testing patterns in metastatic castration-resistant prostate cancer.
Shore N; Ionescu-Ittu R; Yang L; Laliberté F; Mahendran M; Lejeune D; Yu L; Burgents J; Duh MS; Ghate SR
Future Oncol; 2021 Aug; 17(22):2907-2921. PubMed ID: 33906368
[TBL] [Abstract][Full Text] [Related]
6. [Molecular tumor board prostate cancer].
Seitz AK; Heck MM; Kamer MW; Grüllich C
Urologe A; 2019 Jul; 58(7):752-759. PubMed ID: 31049637
[TBL] [Abstract][Full Text] [Related]
7. Towards precision oncology in advanced prostate cancer.
Ku SY; Gleave ME; Beltran H
Nat Rev Urol; 2019 Nov; 16(11):645-654. PubMed ID: 31591549
[TBL] [Abstract][Full Text] [Related]
8. Sequencing Treatment for Castration-Resistant Prostate Cancer.
Handy CE; Antonarakis ES
Curr Treat Options Oncol; 2016 Dec; 17(12):64. PubMed ID: 27822685
[TBL] [Abstract][Full Text] [Related]
9. DNA Repair in Prostate Cancer: Biology and Clinical Implications.
Mateo J; Boysen G; Barbieri CE; Bryant HE; Castro E; Nelson PS; Olmos D; Pritchard CC; Rubin MA; de Bono JS
Eur Urol; 2017 Mar; 71(3):417-425. PubMed ID: 27590317
[TBL] [Abstract][Full Text] [Related]
10. Genetic aberrations of homologous recombination repair pathways in prostate cancer: The prognostic and therapeutic implications.
Saeidi H; Bakrin IH; Raju CS; Ismail P; Saraf M; Khairul-Asri MG
Adv Med Sci; 2023 Sep; 68(2):359-365. PubMed ID: 37757663
[TBL] [Abstract][Full Text] [Related]
11. Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations.
Shore N; Oliver L; Shui I; Gayle A; Wong OY; Kim J; Payne S; Amin S; Ghate S
J Urol; 2021 Apr; 205(4):977-986. PubMed ID: 33332152
[TBL] [Abstract][Full Text] [Related]
12. Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.
Buonerba C; Di Lorenzo G; Sonpavde G
Expert Rev Mol Diagn; 2016 Oct; 16(10):1113-1120. PubMed ID: 27665838
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
Slootbeek PHJ; Tolmeijer SH; Mehra N; Schalken JA
Crit Rev Clin Lab Sci; 2024 May; 61(3):178-204. PubMed ID: 37882463
[TBL] [Abstract][Full Text] [Related]
14. Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
Liu JJ; Zhang J
Cancer Control; 2013 Jul; 20(3):181-7. PubMed ID: 23811702
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
[TBL] [Abstract][Full Text] [Related]
16. Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.
Singhal U; Wang Y; Henderson J; Niknafs YS; Qiao Y; Gursky A; Zaslavsky A; Chung JS; Smith DC; Karnes RJ; Chang SL; Feng FY; Palapattu GS; Taichman RS; Chinnaiyan AM; Tomlins SA; Morgan TM
Mol Cancer Res; 2018 Apr; 16(4):643-654. PubMed ID: 29453313
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for characterization and therapeutic orientation in castration-resistant prostate cancer.
Plata Bello A; Tamayo Jover MA; Gutierrez Nicolas F; Acosta López S; Concepción Masip T; Plata Bello J
Arch Esp Urol; 2022 Mar; 75(2):195-202. PubMed ID: 35332889
[TBL] [Abstract][Full Text] [Related]
18. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
19. Precision medicine for advanced prostate cancer.
Mullane SA; Van Allen EM
Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474
[TBL] [Abstract][Full Text] [Related]
20. GENOMICS OF PROSTATE CANCER: CLINICAL UTILITY AND CHALLENGES.
Šamija I; Fröbe A
Acta Clin Croat; 2022 Oct; 61(Suppl 3):86. PubMed ID: 36938554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]